Rapid delivery of toxicological study material: The new critical path for accelerating biopharmaceutical drug development

As timelines from DNA to IND continue to shorten, the need for faster toxicology material delivery has become increasingly important to start studies as early as possible and avoid delays in IND submissions. In this webinar, Lonza experts will present innovative strategies and technologies that streamline analytical workflows and material supply, helping generate tox material for mAbs and bispecifics in as little as 2.5 months post-transfection, easing pressure on development timelines and mitigating potential bottlenecks in IND-enabling activities.

Key takeaways:

• Maximize speed: Discover our newly developed timelines that can reduce the time to deliver toxicology materials by up to 50%, giving you a head start on your IND submission.
• Ensure compliance: Confidently navigate the regulatory requirements for non-clinical material used in toxicology and IND-enabling studies.
• Enabling technologies and streamlined analytics: Discover lean solutions and technologies that accelerate your material delivery process, along with efficient, robust analytical workflows for toxicology material characterization and release.
• Integrated drug substance/drug product offer: Applying this rapid toxicology material supply approach in rapid clinical timelines is achievable with this new integrated offering.

Watch Now